Proteomics & Phosphoproteomics
Integrated Quantitative Infrastructure for Development-Stage Programs
End-to-end quantitative proteome and phosphoproteome workflows spanning cells, tissue, and plasma — engineered for mechanistic resolution, pharmacodynamic modeling, and translational assay deployment. This unified framework enables disciplined translational advancement from mechanistic discovery through plasma validation to development-ready quantitative assays.
Integrated Proteomic Infrastructure
Proteas Health delivers unified proteome and phosphoproteome measurement across biological compartments, from mechanistic cellular signaling analysis to longitudinal plasma profiling and structured assay translation.
Unlike exploratory discovery laboratories, our workflows are architected for development-stage execution, enabling:
- Mechanism-of-action clarification
- Target engagement confirmation
- Systems-level pharmacodynamic modeling
- Translational progression toward deployable assays
Our infrastructure integrates:
Cellular & Tissue Proteomics
Systems-Level Proteome and Phosphoproteome Characterization
High-resolution quantitative profiling across cells and tissue to resolve signaling modulation, pathway activity, and drug-mediated biological response.
Quantitative Proteome Profiling
Comprehensive measurement of protein abundance to define pathway architecture, response states, and molecular consequences of therapeutic intervention. Outputs are structured for cross-study comparability and mechanistic interpretation.
Integrated Phosphoproteomics
Parallel phosphoproteome quantification to resolve kinase signaling, target engagement, and downstream pathway modulation. Enables direct assessment of drug-induced signaling network remodeling rather than indirect surrogate readouts.
Low-Input Compatibility
Optimized workflows supporting analysis from limited material, including approximately 1 million cells or ~1 mm³ tissue. Designed for translational and early clinical environments where sample availability is constrained.
Development Integration
Standardized quantitative outputs engineered for reproducibility and compatibility with downstream validation, modeling, and assay development workflows.
Plasma Proteomics (BioTAS™)
Longitudinal Systems-Level Drug Response Modeling
Quantitative plasma proteomics and phosphoproteomics enabled by the BioTAS™ platform, integrating controlled pre-analytical handling with high-resolution mass spectrometry and structured modeling. Engineered to resolve systemic pharmacodynamic effects and treatment-adaptive biological remodeling at clinical scale.
Controlled Plasma Measurement
Standardized collection and stabilization minimize pre-analytical variability and enable reproducible protein quantification across decentralized and multi-site programs.
Pharmacodynamic Response Characterization
Longitudinal plasma profiling to evaluate systemic pathway modulation, pleiotropic treatment effects, and treatment-associated signaling shifts.
Stratification & Signature Development
Identification of treatment-responsive protein networks supporting cohort differentiation, response stratification, and companion diagnostic hypothesis generation.
Clinical-Scale Translation
Protein signatures derived from plasma profiling can be advanced into structured multiplexed assays compatible with CLIA-aligned laboratory environments and clinical trial integration.
Quantitative Assay Translation
From Systems Discovery to Development-Ready Measurement
Multiplexed targeted protein panels engineered to confirm, refine, and operationalize signatures derived from discovery-scale proteomics. Designed for precision, reproducibility, and integration within regulated development environments.
Targeted Panel Development
Refinement of candidate signatures into analytically structured, high-specificity quantitative panels optimized for dynamic range and cross-run consistency.
Analytical Performance Characterization
Evaluation of reproducibility, linearity, and inter-operator robustness within standardized workflows to support development-stage requirements.
Development Deployment
Compatibility with multi-site execution and CLIA-aligned laboratory integration, supporting progression toward companion diagnostic strategies or structured clinical trial implementation.